Alejandro Alonso Cabrero

Médico especialista en Hematología y hemoterapia

[GELTAMO @geltamo]

Very early [18F]FDG-PET-guided targeted therapy in untreated advanced-stage classic Hodgkin lymphoma (EORTC-1537-COBRA): primary results of a single-arm, multicentre, phase 2 trial - The Lancet Haematology https://t.co/mU0QRkGOFX

[GELTAMO @geltamo]

Comparative effectiveness of immunotherapy alone or with chemotherapy as first-line treatment for marginal zone lymphoma | Haematologica https://t.co/8ktSYjfist

[GELTAMO @geltamo]

Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy | Journal of Clinical Oncology https://t.co/KlEs6Kfv33

[Pau Abrisqueta @ab_pau]

Ampliamos equipo!
Buscamos hematólogo/a para la Unidad de Ensayos Clínicos @Hemato_Vhebron y otros proyectos científicos🩺🧪
Te apuntas?
(Contactar [email protected])

[Blood Journals Portfolio @BloodPortfolio]

Elevated B12 serum levels are associated with the presence of clonal hematopoiesis https://t.co/8QAHTZfaNV #myeloidneoplasia #clonalhematopoiesis

[Raul Cordoba, MD, PhD @DrRaulCordoba]

#Hematology Treatment of Relapsed and Refractory Follicular #Lymphoma: Which Treatment for Which Patient for Which Line of Therapy? By Carla Casulo & Laurie H. Sehn, at ⁦@BloodPortfolio⁩ | American Society of Hematology ⁦@ASH_hematology⁩ #lymsm https://t.co/0i4GdBsHNG

[Laura Pardo @DraLPardoG]

🎯🫵AML: 2025 Update on Diagnosis, Risk-Stratification, and Management.

https://t.co/R4h5yJGQLo

[Blood Journals Portfolio @BloodPortfolio]

ASCT could still be considered in patients with primary refractory or early relapse in centers with limited access to CAR-T therapy. https://t.co/Biz7FMcxI2 #lymphoidneoplasia #transplantation

[Haematologica @Haematologica]

The emerging problem of infections after bispecific T-cell engager treatment in multiple myeloma: a case series of four patients developing non-tuberculous mycobacterial infections following teclistamab.
https://t.co/FS6IRvcZ8w

[GELTAMO @geltamo]

@geltamo en #18ICML
CENTRAL NERVOUS SYSTEM RELAPSE IN HIGH-GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS:
A MULTICENTER STUDY FROM THE SPANISH GROUP GELTAMO @ab_pau @icmlugano

[Talha Badar @TalhaBadarMD]

#ASH24 Avapritinib in RR or MRD+ cKitm core binding factor AML 👇🏽

Time to response 2-3 cycles

Better responses with MRD+ disease compared to RR #leusm

[Haematologica @Haematologica]

A new paper reviews the associations between acquired aplastic anemia (AA) and germline variants of AA, detailing the clinical significance of germline variants in diagnosing and managing this condition.
https://t.co/Hzj5LpDSBO

[Julio García Suárez @jgarciasu59]

Clonal hematopoiesis of indeterminate potential in patients with immunoglobulin light-chain AL amyloidosis | Blood Advances | https://t.co/6Lg6NbEs2G

[Benlazar S M A @smbenlazar]

Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera | New England Journal of Medicine https://t.co/8HDaK0cl3o #mpnsm

[British Journal of Haematology @BrJHaem]

The @BrJHaem Award 🏆 🥇 for "Top Downloaded paper" is "Guideline on the investigation and management of acute transfusion reactions"
Congrats to all authors! @BritSocHaem
link to paper: https://t.co/HXQ1wcHcKC

[Benlazar S M A @smbenlazar]

Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigation https://t.co/3VqAxpFKAk #lymsm

[Ahmed Kotb @AhmedKo45911157]

✔️Wonderful summarised algorithm for Lymphoma Classification
#lymphoma #classification #NHL

[Benlazar S M A @smbenlazar]

Venetoclax Improves Response Rates but Not Survival in Patients with #CMML Treated with HMA https://t.co/iavGTCK0hn

[Benlazar S M A @smbenlazar]

The Management of Low-Risk Myelodysplastic Syndromes—Current Standards and Recent Advances #MDS https://t.co/kENHP9MxpG

[Naveen Pemmaraju, MD @doctorpemm]

👉👉👉Important New paper just out in @BloodAdvances led by Dr Alex Bataller & Dr Tapan Kadia .@TapKadia || 📣 Prognostic risk signature in patients with AML treated with HMA & VEN | #FLT3 #KRAS #NRAS | @MDAndersonNews #endcancer #leusm | @sanamloghavi

https://t.co/8KcWIe3lsM